Vasileia Kalaitzaki

Vasileia Kalaitzaki

Auto-generated profile, based on publicly available information

Vasileia Kalaitzaki

Institute of Laboratory Animal Science, University of Zurich, Schlieren, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2022 in Glia
Verified
Journal Article
Open access
GLGiuseppe Locatelli
Giuseppe Locatelli
FMFilipa Marques‐Ferreira
Filipa Marques‐Ferreira
AKAntonis Katsoulas
Antonis Katsoulas
VKVasileia Kalaitzaki
Vasileia Kalaitzaki
MKMartin Krueger
Martin Krueger
TBThorsten Buch
Thorsten Buch
In the central nervous system (CNS), insulin-like growth factor 1 (IGF-1) regulates myelination by oligodendrocyte (ODC) precursor cells and shows anti-apoptotic properties in neuronal cells in different in vitro and in vivo systems. Previous work also suggests that IGF-1 protects ODCs from cell death and enhances remyelination in models of toxin-induced and autoimmune demyelination. However, since evidence remains controversial, the therapeutic potential of IGF-1 in demyelinating CNS conditions is unclear. To finally shed light on the function of IGF1-signaling for ODCs, we deleted insulin-like growth factor 1 receptor (IGF1R) specifically in mature ODCs of the mouse. We found that ODC survival and myelin status were unaffected by the absence of IGF1R until 15 months of age, indicating that IGF-1 signaling does not play a major role in post-mitotic ODCs during homeostasis. Notably, the absence of IGF1R did neither affect ODC survival nor myelin status upon cuprizone intoxication or induction of experimental autoimmune encephalomyelitis (EAE), models for toxic and autoimmune demyelination, respectively. Surprisingly, however, the absence of IGF1R from ODCs protected against clinical neuroinflammation in the EAE model. Together, our data indicate that IGF-1 signaling is not required for the function and survival of mature ODCs in steady-state and disease.

31 August 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
ALAndreas Lutterotti
Andreas Lutterotti
TLThomas Ludersdorfer
Thomas Ludersdorfer
MDMaria Jose Docampo
Maria Jose Docampo
MMMuriel Morax
Muriel Morax
HHHelen Hayward-Koennecke
Helen Hayward-Koennecke
RMRoland Martin
Roland Martin
Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial with clinical, imaging, and mechanistic readouts. RBCs coupled with seven immunodominant myelin peptides (pcRBCs) were safe and well tolerated. Several clinical and imaging readouts remained stable, which was supported by a reduction of neurofilament light chain indicating reduced tissue inflammation in the brain. Single-cell RNA sequencing identified expansion of antigen-specific CD4+ memory T cells with regulatory phenotypes and loss of proinflammatory cells three months after a single administration of pcRBCs. This was corroborated by a reduction of autoreactive CD4+ T cell responses and an early increase of IL-10, Tr1 regulatory T cells and tolerogenic monocytes and plasmacytoid dendritic cells. Biodistribution studies in mice and humans demonstrate that pcRBCs are rapidly processed by Kupffer cells in the liver and by marginal zone macrophages in the spleen. In summary, pcRBCs are a promising autologous cell therapy for achieving antigen-specific immune tolerance in MS.

9 October 2026 in Science Advances
Verified
Journal Article
Open access
VKVasileia Kalaitzaki
Vasileia Kalaitzaki
POPietro Oldrati
Pietro Oldrati
FFFilipa M. Ferreira
Filipa M. Ferreira
AKAntonios Katsoulas
Antonios Katsoulas
AAAhmed Ali
Ahmed Ali
TBThorsten Buch
Thorsten Buch
Induction of antigen-specific immune tolerance is the most precise method for reverting an autoreactive immune response in diseases such as multiple sclerosis (MS). Coupling red blood cells (RBCs) with a cocktail of MS immunodominant peptides is a promising approach to induce antigen-specific immune tolerance in patients. Here, we show that RBCs coupled with disease-inducing antigen efficiently prevent the development of experimental autoimmune encephalomyelitis, when administered prophylactically, and ameliorate disease symptoms when given therapeutically. The tolerogenic activity of peptide-coupled RBCs (pcRBC) was antigen specific and dependent on both cell and peptide dose. Kupffer cells (KC) were the primary phagocytes of pcRBC, and their uptake of pcRBC did not require complement component 3, SIRPα, and Stabilin 1 and 2. KC were indispensable for the induction of tolerance, which was accompanied by programmed death-ligand 1 up-regulation and a tolerogenic transcriptional shift. Our findings establish KC as central mediators of pcRBC-induced immune tolerance and provide mechanistic insight for the use of this therapeutic strategy in autoimmune disease.